Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Roila

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)J Herrstedt, M S Aapro, F Roila, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomitingF Roila, C Basurto, V Minotti, et al.
Journal of Chemotherapy (Florence, Italy)|July 1, 1989
Antiemetic therapy in patients treated with cisplatin chemotherapyF Roila, C Basurto, S Bracarda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Delayed emesis following anticancer chemotherapyM G Kris, F Roila, P H De Mulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Management of cancer pain: ESMO Clinical Practice GuidelinesC I Ripamonti, D Santini, E Maranzano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Consensus regarding multiple day and rescue antiemetic therapyP H De Mulder, F Roila, M G Kris, et al.
Oncology|January 1, 1988
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized studyF Roila, C Basurto, V Minotti, et al.
Cancer Investigation|January 1, 1988
A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapyC Basurto, F Roila, A Del Favero, et al.
American Journal of Clinical Oncology|October 1, 1988
A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agentsC Basurto, F Roila, S Bracarda, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1987
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMFF Roila, M Tonato, C Basurto, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)J Herrstedt, M S Aapro, F Roila, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomitingF Roila, C Basurto, V Minotti, et al.
Journal of Chemotherapy (Florence, Italy)|July 1, 1989
Antiemetic therapy in patients treated with cisplatin chemotherapyF Roila, C Basurto, S Bracarda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Delayed emesis following anticancer chemotherapyM G Kris, F Roila, P H De Mulder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Management of cancer pain: ESMO Clinical Practice GuidelinesC I Ripamonti, D Santini, E Maranzano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 18, 1998
Consensus regarding multiple day and rescue antiemetic therapyP H De Mulder, F Roila, M G Kris, et al.
Oncology|January 1, 1988
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized studyF Roila, C Basurto, V Minotti, et al.
Cancer Investigation|January 1, 1988
A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapyC Basurto, F Roila, A Del Favero, et al.
American Journal of Clinical Oncology|October 1, 1988
A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agentsC Basurto, F Roila, S Bracarda, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1987
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMFF Roila, M Tonato, C Basurto, et al.
Pageof 12